BlackRock — 2016 Investments
2 investments dated 2016 · listed companies and verified rows first · show all
Lion Biotechnologies develops and commercializes TIL (tumor infiltrating lymphocyte) cell therapies, individualized immunotherapies manufactured from patient T cells to treat solid tumor cancers, with its lead product Amtagvi approved for previously treated advanced melanoma and a pipeline of combination therapies and monotherapies for additional cancer types.
BiotechNew York, US
Molly C. Henderson(Executive Officer)Michael T. Lotze(Executive Officer)Steven A. Fischkoff(Executive Officer)Maria Fardis(Executive Officer, Director)Frederick G. Vogt(Interim Chief Executive Officer and President, General Counsel)Corleen Roche(Chief Financial Officer)
Savara is a biopharmaceutical company developing product candidates for the treatment of autoimmune pulmonary alveolar proteinosis and related conditions.
BiotechAustin, US
Robert Neville(Executive Officer, Director)John Lord(Executive Officer)Chris Marich(Executive Officer)inTaneli Jouhikainen(Executive Officer)Matthew Pauls(Chief Executive Officer; Chair of the Board of Directors)
BoardYuri Pikover(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.